The North American Menopause Society (NAMS) presents its comprehensive video series for clinicians about important midlife health topics. All of the interviews in the series are hosted by NAMS Board of Trustees Member and President Dr Marla Shapiro, a Canadian physician, who led this exciting initiative. Dr Shapiro is also the medical consultant for CTV News and on-air medical contributor to Canada AM.
Note: The Australasian Menopause Society does not necessarily endorse the medical and scientific information provided in these videos. As the medical and scientific information provided here might not be relevant to a particular person's circumstances and you should always discuss your health with your own healthcare provider.
Professor of Medicine and Preventive Medicine and Director of the Atherosclerosis Research Unit, Keck School of Medicine at the University of Southern California in Los Angeles.
Dr Hodis explains indications and risk factors for the new class of lipid-lowering drugs. In addition, he discusses the gender differences in cardiovascular disease.
Medical Director of the Clinical Research Center at Helen Hayes Hospital and Professor of Medicine at Columbia University College of Physicians and Surgeons in New York.
Dr Cosman explains vertebral and osteoporotic fractures, risk levels, and antiresorptive and anabolic therapies and shares thoughts on drug holidays.
Honorary Senior Lecturer, Imperial College Director, West London Menopause and PMS Center Queen Charlotte’s and Chelsea Westminster Hospitals General Secretary-Elect of the International Menopause Society
Dr Panay reviews why discussion of treatment options for genitourinary syndrome of menopause (GSM) is often overlooked in patient visits. He explains the differences in performance and frequency of use of both moisturizers and lubricants and how the FDA-approved nonestrogen prasterone works.
Past President of NAMS and Associate Chairman and Residency Program Director in the Department of Obstetrics and Gynecology at the Reading Hospital in Reading, Pennsylvania.
Dr Schnatz discusses the benefits of starting women on hormone therapy at the beginning of the menopause transition, along with the cardiovascular health advantages.
Dr Kaunitz is an obstetrician-gynecologist in Jacksonville, Florida and is affiliated with multiple hospitals in the area, including UF Health Jacksonville and UF Health Shands Hospital.
Dr Kaunitz discusses the appropriate type of contraceptive for women, including those at risk.
Past President, The North American Menopause Society Professor, Health Research and Policy and Neurology and Neurological Sciences Stanford University Director, Alzheimer’s Disease Research Center Stanford, CA
Dr Hendersen explains cognitive complaints as it relates to ageing and a decline in oestrogen as well as the cardiovascular connection. He also provides advice for when advanced cognitive testing is required.
Past President of NAMS, Professor of Psychiatry and Psychology, Director of Women’s Mental Health Research, and Research Director at UIC Center for Research in Women and Gender at the University of Illinois at Chicago
Prof Maki discusses the hormone therapy timing hypothesis and cognition, the relationship between cognition and cardiovascular protection, and the latest cognition trials and studies.
Past President of NAMS, an internist, endocrinologist, and reproductive endocrinologist at the University of California, San Diego.
Dr Stuenkel discusses the safety and risk for hormone therapy in women aged 65 years and older.
Past President of NAMS, Professor of Obstetrics and Gynecology at New York University School of Medicine, and Co-Director of the Bone Densitometry and Body Composition unit at the NYU Langone Medical Center.
Dr Goldstein discusses discusses vaginal ultrasound for postmenopause bleeding and when clinicians should refer women for ultrasound.
NAMS Board Member and Founding Director of the Oregon Osteoporosis Center in Portland, Oregon.
Dr McClung discusses the right timing for drug holidays from bisphosphonates for women at low risk and as well as follow-up procedures. He discusses those who should not consider a drug holiday.
